Zacks Investment Research upgraded shares of Yield10 Bioscience (NASDAQ:YTEN) from a sell rating to a hold rating in a research note published on Sunday morning, reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Several other research analysts have also issued reports on the company. National Securities restated a buy rating and issued a $5.00 price target on shares of Yield10 Bioscience in a research report on Tuesday, August 20th. Aegis restated a buy rating and set a $2.00 target price on shares of Yield10 Bioscience in a report on Tuesday, August 13th. Finally, Maxim Group restated a buy rating and set a $3.00 target price on shares of Yield10 Bioscience in a research report on Friday, May 31st.

Shares of NASDAQ:YTEN opened at $0.64 on Friday. The company has a current ratio of 3.33, a quick ratio of 3.33 and a debt-to-equity ratio of 1.17. Yield10 Bioscience has a 1-year low of $0.60 and a 1-year high of $1.77. The stock has a market capitalization of $8.01 million, a P/E ratio of -0.70 and a beta of 3.05. The business has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $1.00.

Yield10 Bioscience (NASDAQ:YTEN) last posted its quarterly earnings results on Monday, August 12th. The specialty chemicals company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.06. Yield10 Bioscience had a negative net margin of 1,320.21% and a negative return on equity of 145.61%. The business had revenue of $0.32 million during the quarter. As a group, equities analysts predict that Yield10 Bioscience will post -0.66 EPS for the current year.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Renaissance Technologies LLC increased its holdings in shares of Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 478,176 shares of the specialty chemicals company’s stock after buying an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned 3.83% of Yield10 Bioscience worth $463,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 7.69% of the company’s stock.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Recommended Story: Growth Stocks

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with's FREE daily email newsletter.